AR022303A1 - Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion - Google Patents
Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacionInfo
- Publication number
- AR022303A1 AR022303A1 ARP000100197A ARP000100197A AR022303A1 AR 022303 A1 AR022303 A1 AR 022303A1 AR P000100197 A ARP000100197 A AR P000100197A AR P000100197 A ARP000100197 A AR P000100197A AR 022303 A1 AR022303 A1 AR 022303A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr6r7
- disorders
- piperazine
- piperidine
- disorder
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100243950 Arabidopsis thaliana PIE1 gene Proteins 0.000 abstract 1
- 206010010219 Compulsions Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Un derivado de piperidina, tetrahidropiridina o piperazina, que tiene la formula (1) cualquiera de sus enantiomeros o cualquier mezcla de los mismos, o unasal de adicion de ácido de los mismos, en la cual: B representa alquileno C1-10, alquenileno C2-10 o alquinileno C2-10; X es -O-, -S-, o CR4R5-; e Y es-CR6R7-, -CR6R7-CR8R9-, o -CR6=CR7; o X e Y forman conjuntamente un grupo -CR4=CR5-, o -CR4=CR5-CR6R7-; Z es -O- o -S-; W es N, C, o CH, y la línea de puntoses un enlace opcional; A es un anillobicíclico seleccionado de entre la formulas (2) o (3) siendo E1, E2, y E3, seleccionados de entre el grupo consistente enO, S, N, NR11, C, CR12 y CHR13, y la línea de puntos representa un enlace opcional, con la condicion que E2 y E1 y/o E3 no pueden ser simultáneamente O ni S;los restantes sustituyentes figuran definidos en la memoria descriptiva. Los compuestos de la presente son considerados utiles para el tratamiento de lostrastornos afectivos, tales como la depresion, sicosis, trastornos tipo ansiedad que incluyen el trastorno general de la ansiedad, el trastorno tipo pánico, eltrastorno de la compulsion obsesiva, y los trastornos de la alimentacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900084 | 1999-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022303A1 true AR022303A1 (es) | 2002-09-04 |
Family
ID=8089560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100197A AR022303A1 (es) | 1999-01-22 | 2000-01-17 | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6596722B2 (es) |
| EP (1) | EP1149087B1 (es) |
| JP (1) | JP2002535322A (es) |
| KR (1) | KR20010101606A (es) |
| CN (1) | CN1344265A (es) |
| AR (1) | AR022303A1 (es) |
| AT (1) | ATE263763T1 (es) |
| AU (1) | AU767377B2 (es) |
| BG (1) | BG105781A (es) |
| BR (1) | BR0009007A (es) |
| CA (1) | CA2361059A1 (es) |
| CZ (1) | CZ20012657A3 (es) |
| DE (1) | DE60009663T2 (es) |
| EA (1) | EA200100798A1 (es) |
| HK (1) | HK1045505A1 (es) |
| HU (1) | HUP0105065A3 (es) |
| IL (1) | IL144113A0 (es) |
| IS (1) | IS5983A (es) |
| MX (1) | MXPA01007226A (es) |
| NO (1) | NO20013538L (es) |
| NZ (1) | NZ512732A (es) |
| PL (1) | PL349909A1 (es) |
| SK (1) | SK10302001A3 (es) |
| TR (1) | TR200102089T2 (es) |
| WO (1) | WO2000043382A1 (es) |
| ZA (1) | ZA200105548B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1007523B9 (en) * | 1997-07-25 | 2004-09-08 | H. Lundbeck A/S | Indole and 2,3-dihydroindole derivatives, their preparation and use |
| US7067513B1 (en) * | 1999-08-23 | 2006-06-27 | Solvay Pharmaceuticals B.V. | Phenylpiperazines |
| AR027133A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
| EP1408976B3 (en) * | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| JP2005504043A (ja) * | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7235569B2 (en) | 2003-05-02 | 2007-06-26 | Wyeth | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use |
| US7276603B2 (en) | 2003-05-02 | 2007-10-02 | Wyeth | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7371769B2 (en) | 2004-12-07 | 2008-05-13 | Solvay Pharmaceuticals B.V. | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| US20060122175A1 (en) * | 2004-12-07 | 2006-06-08 | Solvay Pharmaceuticals B.V. | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| US20070072870A2 (en) | 2004-12-08 | 2007-03-29 | Solvay Pharmeceuticals B.V. | Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| DE602005010902D1 (de) * | 2004-12-08 | 2008-12-18 | Solvay Pharm Bv | Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung |
| DE102004063797A1 (de) * | 2004-12-30 | 2006-07-13 | Schwarz Pharma Ag | Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| KR100589877B1 (ko) * | 2005-12-20 | 2006-06-19 | 주식회사 픽슨이앤씨 | 파형강판 구조물의 보강라이너 설치용 거푸집 |
| NZ571300A (en) | 2006-04-07 | 2011-12-22 | Warner Chilcott Co Llc | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof |
| US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| SG10201505672TA (en) | 2009-07-06 | 2015-09-29 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| CN103380129B (zh) | 2010-12-20 | 2016-04-20 | 阿克图拉姆生命科学股份公司 | 2-甲酰胺-4-哌嗪基-苯并呋喃衍生物 |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| EP3027607B1 (en) | 2013-07-29 | 2020-08-26 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use thereof |
| CN104725363B (zh) * | 2013-12-20 | 2019-03-01 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| WO2016192657A1 (en) * | 2015-06-03 | 2016-12-08 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| FR2670491B1 (fr) * | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| RU2118322C1 (ru) * | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
-
2000
- 2000-01-17 AR ARP000100197A patent/AR022303A1/es not_active Application Discontinuation
- 2000-01-21 JP JP2000594798A patent/JP2002535322A/ja not_active Withdrawn
- 2000-01-21 CZ CZ20012657A patent/CZ20012657A3/cs unknown
- 2000-01-21 CA CA002361059A patent/CA2361059A1/en not_active Abandoned
- 2000-01-21 CN CN00805148A patent/CN1344265A/zh active Pending
- 2000-01-21 EP EP00901481A patent/EP1149087B1/en not_active Expired - Lifetime
- 2000-01-21 AU AU22781/00A patent/AU767377B2/en not_active Ceased
- 2000-01-21 IL IL14411300A patent/IL144113A0/xx unknown
- 2000-01-21 MX MXPA01007226A patent/MXPA01007226A/es not_active Application Discontinuation
- 2000-01-21 SK SK1030-2001A patent/SK10302001A3/sk unknown
- 2000-01-21 WO PCT/DK2000/000026 patent/WO2000043382A1/en not_active Ceased
- 2000-01-21 AT AT00901481T patent/ATE263763T1/de not_active IP Right Cessation
- 2000-01-21 KR KR1020017009122A patent/KR20010101606A/ko not_active Withdrawn
- 2000-01-21 DE DE60009663T patent/DE60009663T2/de not_active Expired - Fee Related
- 2000-01-21 TR TR2001/02089T patent/TR200102089T2/xx unknown
- 2000-01-21 PL PL00349909A patent/PL349909A1/xx not_active Application Discontinuation
- 2000-01-21 EA EA200100798A patent/EA200100798A1/ru unknown
- 2000-01-21 HK HK02106884.4A patent/HK1045505A1/zh unknown
- 2000-01-21 NZ NZ512732A patent/NZ512732A/en unknown
- 2000-01-21 BR BR0009007-7A patent/BR0009007A/pt not_active IP Right Cessation
- 2000-01-21 HU HU0105065A patent/HUP0105065A3/hu unknown
-
2001
- 2001-06-28 IS IS5983A patent/IS5983A/is unknown
- 2001-07-05 ZA ZA200105548A patent/ZA200105548B/en unknown
- 2001-07-09 US US09/901,585 patent/US6596722B2/en not_active Expired - Fee Related
- 2001-07-17 NO NO20013538A patent/NO20013538L/no not_active Application Discontinuation
- 2001-08-03 BG BG105781A patent/BG105781A/xx unknown
-
2002
- 2002-05-16 US US10/147,950 patent/US20020173512A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL349909A1 (en) | 2002-10-07 |
| BG105781A (en) | 2002-05-31 |
| HUP0105065A3 (en) | 2003-06-30 |
| CN1344265A (zh) | 2002-04-10 |
| US20020173512A1 (en) | 2002-11-21 |
| HK1045505A1 (zh) | 2002-11-29 |
| CZ20012657A3 (cs) | 2002-02-13 |
| US6596722B2 (en) | 2003-07-22 |
| AU767377B2 (en) | 2003-11-06 |
| JP2002535322A (ja) | 2002-10-22 |
| EP1149087A1 (en) | 2001-10-31 |
| EP1149087B1 (en) | 2004-04-07 |
| DE60009663D1 (de) | 2004-05-13 |
| US20020035113A1 (en) | 2002-03-21 |
| CA2361059A1 (en) | 2000-07-27 |
| IS5983A (is) | 2001-06-28 |
| BR0009007A (pt) | 2001-11-27 |
| HUP0105065A2 (hu) | 2002-07-29 |
| DE60009663T2 (de) | 2005-04-14 |
| TR200102089T2 (tr) | 2002-07-22 |
| NO20013538D0 (no) | 2001-07-17 |
| IL144113A0 (en) | 2002-05-23 |
| WO2000043382A1 (en) | 2000-07-27 |
| AU2278100A (en) | 2000-08-07 |
| NO20013538L (no) | 2001-09-17 |
| ZA200105548B (en) | 2002-07-05 |
| EA200100798A1 (ru) | 2001-12-24 |
| NZ512732A (en) | 2003-10-31 |
| MXPA01007226A (es) | 2002-04-24 |
| KR20010101606A (ko) | 2001-11-14 |
| SK10302001A3 (sk) | 2002-01-07 |
| ATE263763T1 (de) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022303A1 (es) | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion | |
| AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| ES2124707T3 (es) | Compuestos heterociclicos y su preparacion y utilizacion. | |
| PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
| ES2054872T3 (es) | Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht. | |
| UY27952A1 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| AR013085A1 (es) | Compuestos derivados de macrolidos c-4'' sustituidos, composicion farmaceutica, metodo de preparacion, compuestos intermediarios para su preparacion | |
| GT199800046A (es) | Compuestos de pirazina. | |
| AR029811A1 (es) | Un procedimiento para la preparacion de una sal de citalopram, base cristalina de citalopram obtenida por dicho procedimiento y una composicion farmaceutica | |
| UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
| ES2052675T3 (es) | 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos. | |
| ES2171428T3 (es) | Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. | |
| ES2065755T3 (es) | Derivados de 3-aminopiridacinas activos sobre el sistema nervioso central. | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| ES2086579T3 (es) | Antagonista de leucotrieno b4. | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| ES2090024T3 (es) | Compuestos de cefemo y procedimientos para su preparacion. | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| PA8458301A1 (es) | 2-aminopiridinas con sustituyentes alcoxi ramificados | |
| AR049464A1 (es) | Antagonistas de receptores de acetilcolina muscarinicos. composiciones farmaceuticas | |
| ES2062758T3 (es) | Nuevos analogos de vitamina d. | |
| AR041786A1 (es) | Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento | |
| ES2188743T3 (es) | Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos. | |
| AR013152A1 (es) | Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |